Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction

Journal of Hypertension

Volumn 27, Issue 11, 2009, Pages 2192-2200

  Leibovitz, Eyal ^a   Ebrahimian, Talin ^a   Paradis, Pierre ^a   Schiffrin, Ernesto L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Aldosterone; Artery stiffness; Endothelial function; Hypertension; Monocytes

Indexed keywords

ACETYLCHOLINE; ALDOSTERONE; ANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ELASTIN; FIBRONECTIN; HYDROETHIDINE; MONOCYTE MACROPHAGE MARKER ANTIBODY; NORADRENALIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ADOLESCENT; ALBERS SCHOENBERG DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONFOCAL LASER MICROSCOPY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOPENIA; MACROPHAGE; MESENTERIC ARTERY; MONOCYTE; MOUSE; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STAINING;

EID: 73249125832     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328330a963     Document Type: Article

References (18)

1. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004; 110:2233-2240.
2. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71:12A-16A.
3. Bunda S, Liu P, Wang Y, Liu K, Hinek A. Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-l receptors in a mineralocorticoid receptor-independent manner. Am J Pathol 2007; 171:809-819. (Pubitemid 47440980)
4. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colonystimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vase Biol 2005; 25:2106-2113. (Pubitemid 41416308)
5. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107:1055-1061. (Pubitemid 32422899)
6. Gekle M, Mildenberger S, Freudinger R, Grossmann C. Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone. Pflugers Arch 2007; 454:403-413. (Pubitemid 46742428)
7. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 1995; 760:109-126.
8. Grossmann C, Krug AW, Freudinger R, Mildenberger S, Voelker K, Gekle M. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab 2007; 292:E1790-E1800. (Pubitemid 47084715)
9. Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 2006; 47:609-613. (Pubitemid 44309681)
10. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, lshii C, Ohno K, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents postinfarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107:2559-2565. (Pubitemid 36628936)
11. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106:2848-2853. (Pubitemid 35396986)
12. Neves MF, Endemann D, Amiri F, Virdis A, Pu Q, Rozen R, et al. Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. J Hypertens 2004; 22:959-966.
13. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
14. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS, et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 2005; 46:555-561. (Pubitemid 41376837)
15. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008; 51:432-439. (Pubitemid 351156429)
16. Sugiyama T, Yoshimoto T, Hirono Y, Suzuki N, Sakurada M, Tsuchiya K, et al. Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochem Biophys Res Commun 2005; 336:163-167. (Pubitemid 41253417)
17. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40:504-510.
18. Zhang A, Jia Z, Guo X, Yang T. Aldosterone induces epithelialmesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol 2007; 293:F723-F731. (Pubitemid 47403342)